Immix Biopharma (IMMX)
(Delayed Data from NSDQ)
$1.89 USD
-0.02 (-1.05%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $1.88 -0.01 (-0.53%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth B Momentum C VGM
Income Statements
Fiscal Year end for Immix Biopharma, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 16 | 8 | 1 | 0 | 1 |
Income After Depreciation & Amortization | -16 | -8 | -1 | 0 | -1 |
Non-Operating Income | 1 | 0 | -23 | -1 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -16 | -8 | -24 | -1 | -1 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -16 | -8 | -24 | -1 | -1 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -15 | -8 | -24 | -1 | -1 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -16 | -8 | -1 | 0 | -1 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -16 | -8 | -1 | 0 | -1 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 17.34 | 13.89 | NA | NA | NA |
Diluted EPS Before Non-Recurring Items | -0.89 | -0.59 | NA | NA | NA |
Diluted Net EPS (GAAP) | -0.89 | -0.59 | -6.64 | -0.34 | NA |
Fiscal Year end for Immix Biopharma, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 4.70 | 5.59 | 5.38 | 4.53 | 3.72 |
Income After SG&A, R&D, and Dept/Amort Expenses | -4.70 | -5.59 | -5.38 | -4.53 | -3.72 |
Non-Operating Income | 0.31 | 0.27 | 0.23 | 0.19 | 0.13 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -4.40 | -5.32 | -5.15 | -4.34 | -3.59 |
Income Taxes | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
Minority Interest | -0.01 | -0.07 | -0.07 | -0.06 | -0.02 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -4.41 | -5.33 | -5.16 | -4.34 | -3.60 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -4.39 | -5.26 | -5.09 | -4.28 | -3.58 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 23.44 | 21.40 | 18.58 | 15.04 |
Diluted EPS Before Non-Recurring Items | -99,999.00 | -0.22 | -0.24 | -0.23 | -0.24 |
Diluted Net EPS (GAAP) | -0.15 | -0.22 | -0.24 | -0.23 | -0.24 |